Trans-Hit Biomarkers - Access To Animal Models
disease, Biomarkers, Animal Models
Animal models are often critical for establishing a first and rapid proof-of-principal for a new drug candidate or a new diagnostic biomarker. Unfortunately, animal models do not always fully reflect the human pathophysiology of a given indication, leading to difficult translational research studies. Therefore, it is essential to carefully select the animal model to be employed. Use of the appropriate animal model will provide a "Go/No Go" milestone, supporting a decision to terminate or advance the project into the next development stage.
Some preclinical animal models offer the ability to identify and measure biomarkers in biological samples before and during the development of a disease
(each animal is its own control), under perfectly controlled experimental conditions. Collecting similar human samples before and during disease would require long and costly prospective studies that would severely limit the advancement of research and development. When possible for animal models, an access to imaging technologies including MRI and µPET, could be very useful for correlating a given biomarker with an anatomical or functional disease-induced change.Trans-Hit Biomarkers has established partnerships with CROs which are world-renowned for their expertise in preclinical assessments and evaluation of novel therapeutic agents or biomarkers. Animal models selected for translational research ideally should allow repetitive samplings. In addition, selected preclinical CRO partners have extensive knowledge and expertise in their respective fields of specialization, offering Trans-Hit Biomarkers and its clients the ability to evaluate the pertinence of their biomarkers.
Examples of animal models available through our CRO partners:
Xenograft and Orthotopic Animal Models of Cancers, Metabolic Syndrome, Diabetes and Diabetes Complications, Atherosclerosis, Myocardial Infarction, Benign Prostratic Hypertrophy and Prostatitis, Interstitial Cystitis .. and others